|
3rd Quarter Profit and Loss Results
2011.11.14
|
|---|
|
Daehan New Pharm Co., Ltd.’s sales for the January to September period reached 34.1 billion KRW, maintaining a similar level to the previous year. Operating profit increased by 9.8% year-on-year to 4.3 billion KRW (operating profit margin 12.6%) due to results from restructuring and operational efficiency improvements. However, net income decreased by 1.3 billion KRW to 560 million KRW (net profit margin 1.6%), mainly due to litigation costs of 1.94 billion KRW incurred in early July, which were accounted for in the first half of the year. The company is currently appealing and the lawsuit is ongoing.
Daehan New Pharm is proactively responding to the challenging business environment in the pharmaceutical industry, including drug price reductions, through management innovation initiatives under the mindset of "START-UP Daehan New Pharm Project."
Along with strategic innovation to become the top specialist company in the Med Health (Welling) field, Daehan New Pharm is accelerating efforts to secure core competencies and modernize systems by restructuring product portfolios, strengthening distribution competitiveness, establishing a cash flow and profit-centered operating system, and fostering key talent with performance-based human resource management. The company expects that the first phase of innovation activities this year will be a strategic turning point yielding breakthrough results, and it is committed to continuously driving innovation to make this crisis a launching pad for its second leap forward. |


Home